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Transient increases in albumin and hyaluronan in 
bronchoalveolar lavage fluid after quitting smoking: 
possible signs of reparative mechanisms 
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“Department of Medicine, Division of Respiratory Medicine and tClinica1 Chemistry and Blood Coagulation, 
Karolinska Hospital, Stockholm, Sweden 
Inhalation of tobacco smoke results in an accumulation of cells in the lower respiratory tract. The 
inflammatory response in the alveoli and lung interstitium may also be reflected by increased bronchoalveolar 
lavage (BAL) fluid concentrations of extracellular matrix components. The present study investigated the 
influence of smoking on the BAL fluid concentrations of albumin (ALB), hyaluronan (HA) and fibronectin 
(FN). Lavage fluids from 18 smokers were analysed before and at 1, 3, 6, 9 and 15 months after smoking 
cessation. Never-smokers (n= 112) served as a reference group. The total cell concentration and the 
concentrations of macrophages, lymphocytes, neutrophils and eosinophils were higher (P<O.OOl-0.01) in 
smokers’ BAL fluid than in never-smokers’, but the values returned to normal within 9 months of smoking 
cessation. The HA concentration was higher (P<O.OOl) in smokers’ than in never-smokers’ BAL fluid, but FN 
and ALB did not differ. Transient increases in the concentrations of ALB and HA (WO.01 for both) was 
observed within 6 months of smoking cessation. These findings indicate a temporary heightened alveolar- 
capillary permeability and an increased production and/or degradation of HA, being enhanced following 
smoking cessation. The findings probably reflect an initiation of a reparative process. 
Introduction 
Smoking has substantial effects on the general 
immune and inflammatory reactions. For instance, 
leukocytosis and alterations in antibody concen- 
trations are well-known effects of tobacco-smoke 
exposure (I). The lung is the major target organ for 
the inhaled smoke, resulting in an accumulation of 
inflammatory cells both in the conducting airways 
and in the alveoli. As a consequence, the number of 
cells recovered by bronchoalveolar lavage (BAL) is 
known to be increased by a factor of 4-5 in human 
smokers compared to non-smokers (24). 
Inflammatory processes in the alveoli influence 
the conditions in the interstitium to a great extent. 
The interstitial tissue is primarily built up by fibro- 
blasts and extracellular macromolecules such as 
fibronectin, hyaluronan and collagen. These compo- 
nents are elevated in BAL fluid from patients with 
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interstitial lung diseases (5510) and are involved 
in the pathogenetic mechanisms leading to fibrosis 
(11). 
The present study was undertaken to evaluate how 
smoking-induced inflammation is associated with 
changes in the production/degradation of extra- 
cellular matrix components, as reflected by their 
concentrations in BAL fluid. The authors focused on 
the effects of smoking cessation on the alveolar 
accumulation of these components, by performing 
BAL in a group of heavy smokers before and repeat- 
edly after smoking cessation. Healthy non-smokers 
served as a reference group. 
Materials and Methods 
SUBJECTS 
The ‘smokers’ consisted of 18 subjects with a 
cigarette consumption of 22.6 & 7.8 (mean & SD) pack 
years. Their mean age was 41.4 years (range 27-61 
years), and 17 were women. Bronchoalveolar lavage 
was performed before and at five different occasions 
after smoking cessation. All subjects underwent the 
lavages within a 6-week period. There were no signs 
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of respiratory tract infection at the time of the 
lavages. Some of the subjects were excluded from the 
study because of a relapse in smoking. Consequently, 
14, 13, 10, 9 and 8 subjects underwent BAL at 1, 3, 6, 
9 and 15 months after smoking cessation, respect- 
ively. In addition, venous blood samples were drawn 
at different time points (0, 9 and 15 months). One 
hundred and twelve healthy never-smokers (72 
females, mean age 28 years, range 18-51 years) who 
underwent BAL at the authors’ clinic from 1984 to 
1992 served as a reference group. The soluble com- 
ponents of BAL fluid were analysed in 56 of these 
subjects (33 females, mean age 28 years, range 19-51 
years), and native fibronectin (FN) was analysed in 
30. All non-smoking and smoking subjects were free 
of medication and had a normal chest X-ray. The 
study had the approval of the local Ethics Committee 
and informed consent was obtained. 
BRONCHOALVEOLAR LAVAGE 
Bronchoalveolar lavage was carried out with a 
flexible fibre-optic bronchoscope (Olympus BF Type 
4B2, Olympus Optical Co Ltd, Japan). Briefly, the 
bronchoscope was wedged in a middle lobe bronchus 
and 37°C sterile saline solution was instilled in five 
aliquots of 50 ml each. The fluid was gently suctioned 
back and collected in a siliconized bottle kept on ice, 
which was immediately transported to the laboratory. 
PREPARATION OF BAL CELLS 
The BAL fluid was strained through a double layer 
of Dacron nets (Millipore, Cork, Ireland). Alveolar 
cells were pelleted by centrifugation at 400 x g, 4°C 
for 10 min and the supernatants were poured off. 
Aprotinin (Trasylola, Bayer AG, Leverkusen, 
Germany), containing 10 000 kallikrein inactivator 
units (KIU) aprotinin ml - ‘, was added to portions 
of the supernatant to a final concentration of 
50 KIU ml - ’ BAL fluid. This was done in order to 
prevent in vitro degradation of fibronectin (8). The 
BAL supernatants were kept frozen at - 70°C until 
further analysis. 
The total number of cells was counted in a Btirker 
chamber and the viability was tested by the exclusion 
of Trypan blue. Smears for differential counts were 
prepared by cytocentrifugation at 500 rpm for 3 min 
(Cytospin 2 Shandon, Southern Products Ltd, 
Runcorn, U.K.). Smears were stained with May- 
Grtinwald Giemsa and 500 cells were counted. 
ANALYSIS OF SOLUBLE COMPONENTS IN BAL FLUID 
Albumin 
Albumin (L-ALB) was determined by rocket 
immunoelectrophoresis (12) using rabbit anti-human 
albumin (Dakopatts, Copenhagen, Denmark) as 
anti-serum and human serum albumin (Kabi, 
Stockholm, Sweden) as standard. Intra-assay and 
inter-assay CVs were 3% and 7%, respectively. 
Hyaluronan 
Hyaluronan (L-HA) was analysed by a radiometric 
assay similar to that of Engstrom-Laurent et al. 
(13) using the Pharmacia HA test kit (Pharmacia, 
Uppsala, Sweden). Intra-assay and inter-assay CVs 
were 4% and 6%, respectively. 
Fibronectin 
Fibronectin (L-FN) was analysed by a double 
sandwich enzyme-linked immunosorbent assay 
(ELISA) (8). Intra-assay and inter-assay CVs were 
4% and 6%, respectively. 
Nativejibronectin 
Native fibronectin (L-nFN) was determined by a 
gelatin-antibody sandwich ELISA (8,14). Intra-assay 
and inter-assay CVs were 3% and 6%, respectively. 
STATISTICAL ANALYSIS 
Medians with interquartile ranges (IQR) are given 
unless otherwise stated. Significance levels between 
the smokers and ex-smokers were evaluated using the 
paired Wilcoxon rank sum test, and between non- 
smokers and smokers/ex-smokers with the Mann- 
Whitney U-test. Due to a large number of parameters 
assessed, a significance level of 1% (PcO.01) was 
considered significant (15). 
Results 
ROUTINE BLOOD AND SERUM COMPONENTS 
The blood haemoglobin (Hb) concentration and 
the white blood cell count (WBC) decreased after 
smoking cessation and were significantly lower at 9 
months after smoking cessation (Table 1). In con- 
trast, the serum concentrations of immunoglobulin 
G (IgG) were higher at 9 and 15 months, although 
the increment did not reach statistical significance. 
However, all the values were within the reference 
values of the authors’ laboratory (120-160 g l- ‘, 
411 x lo9 1~ i and 7.3-17.8 g 1~ ‘, respectively). 
GENERAL LAVAGE DATA 
The recovery of the instilled fluid was higher in 
non-smokers (NSm, median 72%, IQR 68-76, 
n=ll2) than in smokers (Sm, 59.5%, IQR 56661, 
n=18 P<O.OOl). One month following smoking 
cessation, the recovery was 66%, IQR 60-69 (PcO.05 
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Table 1 Blood and serum components in healthy subjects before (0) and 9 and 15 months after 
smoking cessation 
0 (n= 17*j 9 (n=9*) 15 (n=7*) 
Blood haemoglobin 
k-9 
White blood cell count 
(x 1091-r) 
Serum immunoglobulin G 
(g 1~ ‘j 
136 125i- 131 
(130-143) (1222126) (124-135) 
7.7 6.67 6.7 
(7.2-8.4) (6.0-68) (5.777.0) 
8.9 9.5 10.3 
(8.1-9.3) (86108) (9.8-l 1.2) 
n=8 n=8 
Results are given as medians with interquartile ranges: *Unless otherwise stated, significance 
levels are calculated VS. 0. fP<O,Ol (Wilcoxon test for matched pairs). 
Table 2 Cellular findings in bronchoalveolar lavage fluid from smokers (0), ex-smokers (1, 3, 6, 9 and 15 months after 
smoking cessation) and non-smokers 
($18) $14) (& $10) (@Z9) $8) 
Non-smokers 
(n=112)* 
Total cell concentration 31711 
(x 1061F’) (237499) 
Alveolar macrophages 29311 
(x 1061-r) (217427) 
Lymphocytes 
(x 1061-r) 
23.211 
(10.1-32.2) 
Neutrophils 
(x 1061-r) 
2.Q 
(1.3-9.4) 
Eosinophils 
(x 1061-‘) 
0.85 
(O-1.3) 
195911 
(150-227) 
l=tl! 
(135-212) 
11.95 
(6.5-17.5) 
1-6 
(0.5-2.6) 
0.25 
(O-0.5) 
187tll 
(114207) 
1-m 
(104-186) 
13.15 
(9.0-21.2) 
2.45 
(145.0) 
1031 
(85.3-149) 
87.77 
(679127) 
14.911 
(11.6-20.1) 
2.25 
(1.6-2.8) 
0.25 
(O-04) 
1067 
(71.2-122) 
94.61 
(66.6-109) 
10.0 
(9.0-I 1.8) 
2.3 
(0.7-3.2) 
(0-i. 1) 
91.2 
(684-121) 
82.8 
(62.7-107) 
6.0 
(3-9-9.8) 
0.8 
(061.4) 
(0_00.15) 
85.4 
(67.0-l 15) 
79.5 
(59.33107) 
n=96 
4.8 
(268.4) 
n=96 
0.9 
(0.6-1.6) 
n=96 
(Oi.4) 
n=96 
Results are given as medians with interquartile ranges: *Unless otherwise stated, tP<O,Ol, $P<O.OOl VS. 0 (Wilcoxon test 
for matched pairs); §P<O.Ol, ljPcO.001 VS. non-smokers (Mann-Whitney U-test). 
vs. Sm; P<O.OOl vs. NSm). No further increase in 
recovery was noted over the 15month period. 
The viability of the non-smokers’ cells was 90% 
(IQR 86-94), and did not differ from that of smokers 
(90%; IQR 87-93). There were no significant changes 
in the viability at the sequential lavages after smoking 
cessation. 
The total cell concentration and the alveolar 
macrophage (AM) cell concentration were signifi- 
cantly (P<O.OOl) higher in smokers than non- 
smokers (Table 2). After smoking cessation, the total 
lymphocytes and neutrophils were higher (P~O.001 
for both) in smokers’ BAL fluid than in that of 
non-smokers, but the values were normalized at 15 
months (neutrophils 9 months) after smoking ces- 
sation. The median concentration of eosinophils 
was below 1 x lo6 l- ’ in all groups, but the values 
were higher in smokers compared to non-smokers 
(PCO.01). 
SOLUBLE COMPONENTS IN THE BAL FLUID 
as well as the AM cell concentrations decreased L-albumin 
after 1 month (P<O.OOl), and were still lower at There was no difference in the concentration 
the following lavages. Six months after smoking of L-ALB between smokers and non-smokers 
cessation, there was no. significant difference com- (smokers 37.7 mg 1 - ’ IQR 30.848.1; non-smokers 
pared to non-smokers. Both the concentrations of 34.0 mg l- i, IQR 27.043.0), and the values were 
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P 
n = 13 
I I I 
3 
* 
n = 10 FL=9 
I I (  I I 
6 9 
Months 
n=8 
L-l 
n=55 
+- 
15 NSm 
Fig. I Albumin in bronchoalveolar lavage fluid (L-ALB) 
from non-smokers (NSm), smokers and ex-smokers. O= 
before; 1, 3, 6, 9, 15=months after smoking cessation. The 
boxes cover values within the interquartile ranges (25th and 
75th percentiles) and the central line is at the median. The 
individual values of the smokers/ex-smokers are indicated 
by specific symbols. In the non-smoker group, the 10th and 
90th percentiles are given. *P<O,Ol VS. NSm; tP<O.Ol VS. 0. 
largely unaltered at 1 and 3 months after smok- 
ing cessation (32.7 mg l- r, IQR 27.5-50.0 and 
43,3mgl-‘, IQR 39.9-53.5, respectively). How- 
ever, L-ALB increased significantly at 6 months 
(45.4 mg 1~ ‘, IQR 40.2-60.3; PcO.01) compared to 
the baseline value prior to smoking cessation (Fig. 1). 
This value was also significantly higher (P<O.Ol) 
than the non-smoking reference group. At 9 and 15 
months, the L-ALB (37.3 mg 1~ ‘, IQR 36.7-44.3 and 
32.8 mg 1 - i, IQR 24.3-54.9, respectively) did not 
differ from the smokers or the non-smokers. 
L-hyaluronan 
The concentration of L-HA was higher (P<O.Ol) in 
smokers’ BAL fluid (median 28.6hg l- ‘, IQR 23.0- 
39.0) than in that of non-smokers (lO.Opg I- ‘, IQR 
10.0-29.0). It did not differ significantly 1 month 
after smoking cessation compared to values before 
smoking cessation. The BAL concentrations of HA 
at 1 (38.8pg lP *, IQR 34.0-42.0), 3 (34.Opg l- I, 
IQR 32.041.0) and 6 months (37.5pg lP i, IQR 
34.042.0) were significantly higher (P<O.OOl; 
P<O.OOl and P~0.01, respectively) than those of 
non-smokers. At 9 and 15 months, however, the 
values (29.0 pug 1 - ‘, IQR 27.0-34.0 and 23.3 pug 1~ ‘, 
IQR 21.0-32.0) did not differ from those before 
smoking cessation or from those of non-smokers 
(Fig. 2). 
60-- * * 
. 
: 
. 
- * 
n=18 t t * n=14 n=13 n = 10 n=9 n=* n = 5! 5 
01 3 6 9 15 NSm 
Months 
Eg. 2 Hyaluronan in bronchoalveolar lavage fluid (L-HA) 
from non-smokers (NSm), smokers and ex-smokers. 
O=before; 1, 3, 6, 9, 15=months after smoking cessation. 
The individual values are indicated by specific symbols, as in 
Fig. 1. *P<O.Ol; tP<O.OOl VS. NSm. 
L-Jibronectin 
Neither L-fibronectin (L-FN), L-native fibronectin 
(L-nFN) nor L-nFN expressed as a percentage of 
total L-FN differed between smokers and non- 
smokers. There were no alterations in these levels at 
the different time points following smoking cessation 
(data not shown). 
HYALURONAN AND FIBRONECTIN IN RELATION TO 
ALBUMIN 
The HAlALB ratio was higher (PO.01) in 
smokers (and in the 1, 3 and 6 months ex-smokers) 
compared to non-smokers. Furthermore, the HA/ 
ALB ratio increased (P~0.01) after 1 smoking-free 
month compared to the value prior to smoking 
cessation, but the following ratios did not differ from 
the smokers. The FNlALB and nFN/ALB ratios did 
not differ between smokers and non-smokers, or 
during the sequential lavages after smoking cessation 
(Table 3). 
Discussion 
The present study was performed to determine the 
effects of smoking and smoking cessation on soluble 
inflammatory markers in BAL fluid. The studied 
group showed a lower blood haemoglobin concen- 
tration and white blood cell count following smoking 
cessation, whereas serum IgG was higher than before 
cessation. The results indicate a normalization 
process of reversible changes, since smokers have 
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Table 3 Hyaluronan (HA), fibronectin (FN) and native fibronectin (nFN) in relation to 
albumin (ALB) in bronchoalveolar lavage fluid from smokers (0) ex-smokers (1, 3, 6, 9 and 15 
months after smoking cessation) and non-smokers 
$18) (A4) ($13) $10) (29) (2) Non-smokers 
HA/ALB 04t 1.2*2 O%T 0.8 0.8 0.8 0.5 
(O&1.0) (0.8-1.4) (061.1) (060~9) (0.6-0.9) (04-1.1) (0.3308) 
n=51 
FN/ALB 2.3 1.6 
(1.3-2.7) (1.1-2.4) '(li?Y) (l~kt4) (&O) (l& 
1.5 
(1.0-2.8) 
?I=54 
nFN/ALB 0.5 0.4 0.5 0.6 0.8 0.4 0.7 
(0.3-1.2) (0.3%0.8) (0.2-1.0) (0.5-1.4) (0.3-0.8) (0.3-0.8) (0.5-1.2) 
n=30 
Results are given as medians with interquartile ranges: *P<O.Ol VS. 0 (Wilcoxon test for 
matched pairs); ‘yP<O.Ol; $P<O.OOl VS. non-smokers (Mann-Whitney U-test). 
reportedly higher blood cell counts and lower serum 
IgG than non-smokers (16-19). 
In agreement with others (Z-4), the smokers had an 
elevated total cell concentration and higher concen- 
trations of macrophages, lymphocytes, neutrophils 
and eosinophils in their BAL fluid compared to 
non-smokers. As reported earlier (20), the values 
decreased to the non-smoker level within 6 months 
except for a higher lymphocyte count, which was still 
present at 6 and 9 months after smoking cessation. 
Albumin is believed to enter the alveolar space by 
transudation from the blood plasma (21). Elevated 
concentrations of L-albumin are considered to indi- 
cate an increased alveolar-capillary permeability 
(22,23). This has been described mainly in patients 
with interstitial lung diseases (9,24-27). In the present 
study, as in previous studies (9,25), no difference 
was found between smokers’ and non-smokers’ 
L-albumin. However, a significant increase of L- 
albumin was detected at 6 months after smoking 
cessation which could indicate a transient increase in 
the alveolar-capillary permeability. 
Possibly, this may be related to changes in the 
AM population after smoking cessation. Particles 
deposited in the alveolar space are cleared by endo- 
cytosis by AMs (28). This alveolar clearance is a slow 
process, and the authors have shown previously (20) 
that fluorescent tobacco particles can remain in the 
AMs for more than 2 yr after smoking cessation. The 
concentration of AMs decreased continually after 
smoking cessation. Consequently, the burden of 
tobacco particles on the remaining AMs might there- 
fore be higher, resulting in an AM overload of 
foreign material. Also, the metabolic activity of the 
AM population decreased 1-3 months after smoking 
cessation (29) which could contribute to an impaired 
host defence against the particulate burden. Over- 
loading and impaired defence may, in turn, initiate 
an inflammatory reaction in the alveoli and lung 
interstitium, with increased alveolar-capillary per- 
meability and leakage of albumin from the plasma 
leading to elevated L-albumin. 
Hyaluronic acid (hyaluronan) may take part in 
tissue remodelling during inflammation and repair, 
and may emanate from interstitial fibroblasts (30). 
Increased levels of HA in BAL fluid have been 
described previously in various interstitial lung dis- 
eases (6,9,31-33), but also in experimental models 
such as bleomycin-induced alveolitis in the rat 
(34,35). In the present study, the BAL concentrations 
of HA as well as the HA/ALB ratio were higher in 
smokers’ than in non-smokers’ BAL fluid, indicating 
an increased local production or degradation of HA 
in the lung interstitium. Moreover, the values 
increased significantly during the first months after 
smoking cessation, followed by a decline to the 
non-smoker level. This may signal a reversible 
inflammatory phase in the normalization process. 
Fibronectin has the ability to crosslink and bind to 
cells and other macromolecules in the extracellular 
matrix (5,36,37). The increased concentration of 
fibronectin in BAL fluid from patients with inter- 
stitial lung diseases is considered to be of local origin, 
secreted by activated AMs, fibroblasts and epithelial 
cells (37). Fibronectin is degraded in vivo and in vitro 
(38). To prevent in vitro degradation, a protease 
inhibitor (aprotinin) was added to the BAL fluid 
before storage (8). In the present study, neither total 
FN [in agreement with (8,9)], nFN nor the L-FN/L- 
ALB and L-nFN/L-ALB ratios differed between 
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smokers and non-smokers. Regarding the nFN levels 
in smokers and non-smokers, the present findings 
differ from an earlier report from the authors’ group 
(8) in which the concentration of nFN in the 
BAL fluid of smokers was lower than that from 
non-smokers. The reason for this difference is not 
obvious. 
In conclusion, the cessation of smoking results in 
signs of an increased alveolar-capillary permeability 
and a local production/degradation of extracellular 
matrix components in the lung interstitium. The 
data suggest that this response reflects a reparative 
mechanism after smoking cessation in order to adapt 
to a new alveolar environment. 
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